HK1084603A1 - Use of a lectin pathway-specific complement inhibitors in manufacture of medicaments for preventing or inhibiting tissue damage - Google Patents

Use of a lectin pathway-specific complement inhibitors in manufacture of medicaments for preventing or inhibiting tissue damage

Info

Publication number
HK1084603A1
HK1084603A1 HK06106987.6A HK06106987A HK1084603A1 HK 1084603 A1 HK1084603 A1 HK 1084603A1 HK 06106987 A HK06106987 A HK 06106987A HK 1084603 A1 HK1084603 A1 HK 1084603A1
Authority
HK
Hong Kong
Prior art keywords
medicaments
manufacture
preventing
tissue damage
lectin pathway
Prior art date
Application number
HK06106987.6A
Other languages
English (en)
Inventor
Sek Chung Fung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1084603A1 publication Critical patent/HK1084603A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06106987.6A 2003-02-21 2006-06-20 Use of a lectin pathway-specific complement inhibitors in manufacture of medicaments for preventing or inhibiting tissue damage HK1084603A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44906903P 2003-02-21 2003-02-21
PCT/US2004/005136 WO2004075837A2 (en) 2003-02-21 2004-02-20 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
HK1084603A1 true HK1084603A1 (en) 2006-08-04

Family

ID=32927493

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06106987.6A HK1084603A1 (en) 2003-02-21 2006-06-20 Use of a lectin pathway-specific complement inhibitors in manufacture of medicaments for preventing or inhibiting tissue damage
HK11104750.9A HK1150751A1 (en) 2003-02-21 2011-05-16 Methods for preventing and treating tissue damage associated with ischemia- reperfusion injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11104750.9A HK1150751A1 (en) 2003-02-21 2011-05-16 Methods for preventing and treating tissue damage associated with ischemia- reperfusion injury

Country Status (9)

Country Link
US (2) US20060140939A1 (xx)
EP (2) EP1601377A4 (xx)
JP (1) JP2006518749A (xx)
CN (2) CN101897969B (xx)
AU (1) AU2004216176B2 (xx)
CA (1) CA2515453C (xx)
HK (2) HK1084603A1 (xx)
MX (1) MXPA05008570A (xx)
WO (1) WO2004075837A2 (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
CA2463415C (en) 2001-10-25 2012-02-07 Emory University Catheter for modified perfusion
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
US7827077B2 (en) 2003-05-02 2010-11-02 Visa U.S.A. Inc. Method and apparatus for management of electronic receipts on portable devices
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
ES2522525T3 (es) * 2003-05-15 2014-11-14 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) * 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
AU2013201558B2 (en) * 2004-06-10 2016-03-31 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2465534B1 (en) * 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20080097385A1 (en) * 2004-12-22 2008-04-24 Jakob Vinten-Johansen Therapeutic Adjuncts to Enhance the Organ Protective Effects of Postconditioning
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
JP2009514888A (ja) * 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
CN105641688B (zh) * 2005-12-21 2020-06-09 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
WO2007095154A2 (en) 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
US8491870B2 (en) * 2007-12-21 2013-07-23 Lers Surgical, Llc Method for detection and treatment of aneurysms
HUP0900319A2 (en) * 2009-05-25 2011-01-28 Eotvos Lorand Tudomanyegyetem New peptides, method of producing therof and use thereof
CA2971474C (en) * 2009-10-16 2022-11-22 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
CN103068396B (zh) * 2010-03-02 2016-07-06 诺沃姆德治疗公司 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途
WO2011112575A1 (en) * 2010-03-08 2011-09-15 Wake Forest University Health Sciences Keratin biomaterials for treatment of ischemia
PT2563813E (pt) 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
WO2012006599A2 (en) * 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2894342T3 (es) 2011-04-08 2022-02-14 Univ Leicester Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
CN102304158B (zh) * 2011-05-20 2014-07-30 中国人民解放军第二军医大学 酰化黄酮苷化合物及其在制备补体抑制剂药物中的应用
WO2013006449A2 (en) 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
EP2744820B1 (en) 2011-08-17 2018-07-25 Keranetics LLC Methods for extracting keratin proteins
WO2013025941A1 (en) 2011-08-17 2013-02-21 Keranetics Llc Low protein percentage gelling compositions
AU2012311483B2 (en) * 2011-09-24 2016-03-10 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-inhibitor
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
AU2013267909B2 (en) * 2012-04-06 2018-03-01 Omeros Corporation Compositions and methods of inhibiting MASP-1, MASP-2 and/or MASP-3 for treatment of paroxysmal nocturnal hemoglobinuria
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
CN105051057B (zh) 2012-11-15 2019-11-19 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone
EA201690213A1 (ru) 2013-08-12 2016-07-29 Дженентек, Инк. Композиции и способ лечения связанных с комплементом состояний
CN103788157B (zh) * 2014-02-14 2016-04-06 天津科技大学 绒毛白蜡中一种香豆素衍生物及其制备工艺和应用
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
CA3001128A1 (en) 2015-10-07 2017-04-13 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated eye disorder
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN112638417A (zh) * 2018-06-22 2021-04-09 奥默罗斯公司 用于治疗各种血栓性疾病和病症的抑制masp-2的组合物和方法
CN113395994A (zh) * 2018-12-05 2021-09-14 格雷卡迪亚尔诊断有限公司 用于预防和/或治疗缺血和治疗缺血/再灌注损伤的方法和组合物
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
SG11202111419QA (en) * 2019-04-24 2021-11-29 Univ Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
EP3966226A1 (en) 2019-05-07 2022-03-16 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4240750A1 (en) 2020-11-04 2023-09-13 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
AU2022263683A1 (en) * 2021-04-25 2023-11-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6086868A (en) * 1997-04-30 2000-07-11 Schering Corporation Method for treating or preventing ischemia-reperfusion injury
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002532079A (ja) * 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
CA2360233A1 (en) * 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU781805B2 (en) * 1999-08-13 2005-06-16 Brigham And Women's Hospital Inhibitors of the lectin complement pathway (LCP) and their use
RU2002113381A (ru) * 1999-12-02 2004-01-27 Дженс Христиан ДЖЕНСЕНИУС (DK) MASP-3, комплемент-связывающий фермент и его применение
ATE434661T1 (de) * 2000-07-13 2009-07-15 Helion Biotech Aps Masp-2, ein komplement fixierendes enzym, und dessen verwendungen
CA2433353C (en) 2000-12-28 2017-03-21 Altus Biologics, Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction

Also Published As

Publication number Publication date
US20060140939A1 (en) 2006-06-29
MXPA05008570A (es) 2005-11-04
WO2004075837A2 (en) 2004-09-10
HK1150751A1 (en) 2012-01-13
EP2422812A1 (en) 2012-02-29
EP1601377A4 (en) 2009-07-15
AU2004216176B2 (en) 2008-04-03
CN101897969A (zh) 2010-12-01
CN101897969B (zh) 2014-04-02
CN1750844B (zh) 2010-09-08
JP2006518749A (ja) 2006-08-17
CN1750844A (zh) 2006-03-22
AU2004216176A1 (en) 2004-09-10
CA2515453C (en) 2013-09-24
US20090017031A1 (en) 2009-01-15
CA2515453A1 (en) 2004-09-10
EP1601377A2 (en) 2005-12-07
WO2004075837A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
HK1084603A1 (en) Use of a lectin pathway-specific complement inhibitors in manufacture of medicaments for preventing or inhibiting tissue damage
IL173490A0 (en) 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
IL173513A0 (en) Mitotic kinesin inhibitors
EP1656133A4 (en) INHIBITORS OF MITOTIC KINESINE
HK1098322A1 (en) A gauge for use in a surgical procedure
TWI350175B (en) Mesothelioma therapeutic agent
EP1517904A4 (en) INHIBITORS OF MITOTIC KINESIN
EP1509507A4 (en) INHIBITORS OF MITOTIC KINESIN
EP1556052A4 (en) MITOTIC KINESINE HEMMER
HK1087699A1 (en) Gyrase inhibitors and uses thereof
IL173614A0 (en) N-substituted benzimidazolyl c-kit inhibitors
HK1089167A1 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use 2-
IL175260A0 (en) Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
EP1656140A4 (en) INHIBITORS OF MITOTIC KINESINE
EP1581497A4 (en) INHIBITORS OF MITOTIC KINESINE
EP1578724A4 (en) INHIBITORS OF MITOTIC KINESINE
EP1552835A4 (en) TRANSDERMAL STAMP FOR EXTERNAL USE INCLUDING FENTANYLE
HK1099757A1 (en) Caspase inhibitors and uses thereof
EP1696927A4 (en) MITOTIC INHIBITORS OF KINESIN
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AP2006003703A0 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
GB0312224D0 (en) Medicine packs
EP1697331A4 (en) INHIBITORS OF MITOTIC KINESINE
IL182601A0 (en) The use of a protease or a protease inhibitor for the manufacture of medicaments
EP1658274A4 (en) INHIBITORS OF CATHEPSIN S

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160220